Skip to main content
uniQure N.V. logo

uniQure N.V. — Investor Relations & Filings

Ticker · QURE ISIN · NL0010696654 LEI · 724500RPCTZLFYJZ3S98 US Manufacturing
Open in API
Filings indexed 859 across all filing types
Latest filing 2020-03-06 Director's Dealing
Country NL Netherlands
Listing US QURE

About uniQure N.V.

https://www.uniqure.com/

uniQure N.V. is a gene therapy company focused on developing and commercializing treatments for patients with rare and severe diseases. The company utilizes its adeno-associated virus (AAV) based technology platform to create single-administration therapies with the potential for curative results. Its research and development pipeline is concentrated on liver-directed and central nervous system (CNS) disorders, with a key clinical program targeting Huntington's disease. uniQure aims to deliver transformative medicines by translating scientific innovation into viable treatments.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2020-03-06 English
Regulatory Filings 2020
Regulatory Filings
2020-03-06 English
PRIMARY DOCUMENT
Director's Dealing
2020-03-06 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 2, 2020, by uniQure N.V. It announces the issuance of a press release containing the company's financial results for the full year ended December 31, 2019. The document itself does not contain the financial results or detailed financial statements but rather furnishes the press release as an exhibit. The text explicitly states that the information is furnished and not filed, and it is a current report announcing the results rather than the full annual report. The document length is 3846 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results with key highlights only.
2020-03-03 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or agreements. The text describes the entry into a material definitive agreement for an at-the-market offering program, which is a financing activity. It includes details about the sales agreement with SVB Leerink LLC for selling shares up to $150 million. The document does not contain financial statements or detailed financial results but rather announces a capital raising arrangement. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 6338 characters, which is sufficient to contain substantive information about the financing event, not just a brief announcement or a certification. Hence, the classification is CAP with high confidence.
2020-03-02 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to an at-the-market offering of ordinary shares by uniQure N.V. It includes detailed information about the offering, sales agreement, risk factors, use of proceeds, and other related disclosures. The document is not a financial report, earnings release, or management discussion, but rather a capital raising disclosure document. It is not a brief announcement but a full prospectus supplement with substantive content about the offering terms and related information. Therefore, it fits the category of Capital/Financing Update (CAP).
2020-03-02 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.